FluoGuide A/S (STO:FLUO)

Sweden flag Sweden · Delayed Price · Currency is SEK
40.20
+2.00 (5.24%)
Apr 14, 2026, 5:23 PM CET
Market Cap624.54M +21.0%
Revenue (ttm)318.79K -42.9%
Net Income-57.18M
EPS-4.07
Shares Out16.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,868
Average Volume10,826
Open38.20
Previous Close38.20
Day's Range38.20 - 40.50
52-Week Range28.00 - 47.60
Beta0.36
RSI54.55
Earnings DateMay 27, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLUO
Full Company Profile

Financial Performance

In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.

Financial numbers in DKK Financial Statements